Business Wire

Inotrem Announces Fast Track Designation Granted by U.S. FDA to Nangibotide Development Program for the Treatment of Septic Shock

Share

Inotrem S.A., a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nangibotide development program for the treatment of septic shock. Nangibotide, which Phase IIb has just been cleared by the FDA, is a TREM-1 inhibitor peptide with the potential to restore appropriate inflammatory response, vascular function, and improve post septic shock survival.

Septic shock is the ultimate complication of sepsis. The incidence of septic shock continuously raises and mortality remains elevated (35%) in developed countries. There is currently no specific therapy approved for this indication besides antibiotics and symptomatic treatment. Inotrem’s therapeutic solution has the potential to become the first mechanism-based treatment for septic shock.

Fast track is a designation granted by the FDA that is intended to facilitate and expedite development and review of new drugs to address an unmet medical need in the treatment of a serious life threatening condition and for which nonclinical or clinical data has demonstrated the potential to address this unmet medical need.

“FDA’s decision to grant Fast Track designation to nangibotide development program is an important recognition of both Inotrem’s innovative therapeutic approach in the management of acute inflammation and the critical need for causal therapies in a severe condition such as septic shock" said Jean-Jacques Garaud, CEO and cofounder of Inotrem.

“We look fworward to work closely with the FDA, advance our planned ASTONISH trial, and accelerate our efforts to provide the first effective therapy for septic shock patients”, added Margarita Salcedo Magguilli, CDO of Inotrem.

Inotrem recently received an IND clearance by the FDA for its ASTONISH trial (Phase IIb). The company will begin its planned global multicentric Phase IIb study in septic shock patients later this year. The Phase IIb study will aim at demonstrating efficacy of nangibotide and bring a clinically relevant proof of clinical activity in septic shock patients. In addition, this study intends to validate a personalized medicine approach using soluble TREM-1 as potential companion diagnostic test to identify patients more likely to benefit from nangibotide treatment.

About Inotrem
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European investors: Sofinnova Partners, Andera Partners, Biomed Invest and Inserm Transfert Initiative.
www.inotrem.com

About Nangibotide
Nangibotide is the formulation of the active ingredient LR12, which is a 12 amino-acid peptide prepared by chemical synthesis. LR12 is a specific TREM-1 inhibitor, acting as a decoy receptor and interfering in the binding of TREM-1 and its ligand. In preclinical septic shock models, nangibotide was able to restore appropriate inflammatory response, vascular function, and improved animals’ survival post septic shock.

About ASTONISH Study
The Efficacy, Safety and Tolerability of nangibotide in Patients with Septic Shock (ASTONISH) phase IIb trial is a Randomized, Double-blind, Placebo Controlled Dose Selection Study that will be performed in Europe and in the US. Four hundred and fifty patients are planned to be included in this study in 48 clinical sites. The study will compare the effect of nangibotide at two different doses versus standard of care.

Contact information

Media contact for Inotrem
Anne REIN
S&I
anne.rein@strategiesimage.com
+33 6 03 35 92 05

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Verimatrix Wins TV Technology’s Best of Show for VCAS 5 for DVB26.5.2020 17:45:00 CESTPress release

Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that its VCAS™ 5 for DVB solution is a winner of the 2020 Future Best of Show Awards, presented by TV Technology. The award recognizes VCAS 5 for DVB – a powerful, re-engineered version of its VCAS for DVB Broadcast security solution – as an outstanding new product. “Despite not being able to debut VCAS 5 for DVB at NAB Show, we are thrilled for it to receive such a positive reception by the industry experts who served on Future’s Best of Show Awards panel of judges,” commented Asaf Ashkenazi, COO of Verimatrix. “What makes the next-generation solution stand out is not just its ability to provide the highest level of broadcast security available today, but also its ability to do so while benefitting operators with improved speed, adaptability, scalability and cost savings – as well as a reliable end-user experience.” In April, Verimatrix announced it had f

Mary Kay Unveils Groundbreaking Research During Skin of Color Society Virtual Program26.5.2020 17:32:00 CESTPress release

Mary Kay Inc., a leader in skin care innovation for more than 56 years, continued its ongoing support of the beauty and scientific communities by presenting findings during the 2020 Skin of Color Society Symposium Virtual Program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005633/en/ Dr. Lucy Gildea, Chief Scientific Officer of Mary Kay (Photo: Mary Kay Inc.) Dr. Cristi Gomez, Director, Product Safety & Environmental Toxicology, revealed new research on the science behind LumiVie, an intensive serum by Mary Kay that brightens, energizes and moisturizes skin. As urbanization increases globally, the effects of pollution on skin is a growing concern. Chronic exposure to air pollution has been correlated with visible aging—in particular, the development of pigment spots. Researchers at Mary Kay developed a skincare formulation containing botanical extracts and vitamins B3 and C that is both suitable for sensitive skin

Jefferies to Hold Global Coronavirus Relief Charity Day Dedicated to the Memory of Peg Broadbent on May 27th26.5.2020 17:17:00 CESTPress release

Jefferies confirmed today that it will hold a Global Coronavirus Relief Charity Day tomorrow, Wednesday, May 27, 2020. The firm and its staff will contribute to global charities and relief efforts to assist those suffering from the devastation caused by the Coronavirus global pandemic and will offer investors around the world the opportunity to join these efforts by trading with Jefferies. Jefferies will dedicate this entire effort to their late CFO Peg Broadbent, who was a victim of this terrible disease. As previously announced, Jefferies will donate net commissions from trading on May 27 for all global trading in equities, fixed income and foreign exchange by the firm’s clients. In addition, Jefferies as a firm will donate $1 million directly, and all 3,822 employees worldwide will be given the opportunity to donate to these efforts. These contributions will be allocated to a series of charities on the front lines in fighting this ongoing global pandemic and providing urgently neede

New Automated Optical Inspection from Nordson EFD Verifies Fluid Deposit Placement and Accuracy26.5.2020 16:26:00 CESTPress release

Nordson EFD, a Nordson company (NASDAQ: NDSN), the world’s leading precision fluid dispensing systems manufacturer, introduces OptiSure™ Automated Optical Inspection (AOI) software and confocal laser as add-ons to its existing vision-guided dispensing robots. OptiSure AOI add-ons provide optical assurance of fluid deposit accuracy and integrate seamlessly with Nordson EFD’s proprietary DispenseMotion™ software. Using robots’ existing vision systems to verify fluid deposit widths and diameters, the AOI software determines if dispense requirements have been met. Constant closed-loop feedback provides automated quality control (QC) data, saving manufacturers time and cost. “Optical assurance of fluid deposit accuracy in an off-the-shelf solution is a game changer for our customers,” said Johnathan Titone, global product line manager for automated dispensing systems, Nordson EFD. “We saw a need in the market to integrate automated dispensing and AOI and we’re pleased to provide a market-le

LTI Wins 2020 SAP® Pinnacle Award as the Industry Innovation Partner of the Year26.5.2020 16:13:00 CESTPress release

Larsen & Toubro Infotech (BSE code: 540005, NSE: LTI), a global technology consulting and digital solutions company, has won the 2020 SAP® Pinnacle Award as the Industry Innovation Partner of the Year. This award recognizes LTI’s contribution to delivering best-in-class industry solutions that complement the industry portfolio from SAP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005562/en/ LTI has a long-term relationship with SAP, spanning over 20 years, and is uniquely positioned as a partner, co-Innovator and customer. LTI is a Global Strategic Services Partner, and this partnership enables its participation in the SAP S/4HANA® Movement program to promote and accelerate adoption of SAP S/4HANA. In addition, this partnership enables LTI to work closely with SAP’s industry teams to deliver transformational industry specific solutions such as its Intelligent Construction Enterprise. With its deep industry expertise

Rockwell Automation Issues 2019 Corporate Responsibility Report and Launches New Online Hub for Corporate Responsibility and Sustainability Content26.5.2020 16:00:00 CESTPress release

Rockwell Automation, Inc. (NYSE: ROK), today announced the launch of the annual Corporate Responsibility Report (CRR), highlighting the company’s efforts during 2019. The CRR reflects Rockwell Automation’s commitment to placing corporate responsibility and sustainability practices at the core of its approach to customers, employees, and communities. A global industrial automation and digital transformation leader, Rockwell Automation aims to be a principal voice in the corporate responsibility and sustainability space. The 2019 CRR highlights the company’s successful initiatives to continue to build a more inclusive workplace for employees; help customers reduce emissions and waste; and be a catalyst for progress in local communities. In conjunction with the publication of the 2019 CRR, Rockwell Automation today launched a new corporate responsibility content hub. Rockwell Automation’s corporate responsibility content hub will feature new stories and updates on its corporate responsibi